- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Patent holdings for IPC class C07D 333/20
Total number of patents in this class: 558
10-year publication summary
|
35
|
29
|
34
|
34
|
24
|
19
|
19
|
9
|
26
|
13
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The General Hospital Corporation | 4740 |
10 |
| Takeda Pharmaceutical Company Limited | 2708 |
8 |
| Syngenta Participations AG | 1904 |
7 |
| The Broad Institute, Inc. | 1827 |
7 |
| Newron Pharmaceuticals S.p.A. | 62 |
7 |
| Teva Pharmaceutical Industries Ltd. | 783 |
7 |
| Teva Pharmaceuticals USA, Inc. | 891 |
7 |
| Idemitsu Kosan Co., Ltd. | 4224 |
6 |
| Immunomet Therapeutics Inc. | 31 |
6 |
| Texas Heart Institute | 105 |
6 |
| UCB Pharma GmbH | 88 |
6 |
| Regenacy Pharmaceuticals, LLC | 26 |
6 |
| Shanghai Leado PharmaTech Co. Ltd. | 16 |
6 |
| The Regents of the University of California | 19961 |
5 |
| Massachusetts Institute of Technology | 10062 |
5 |
| President and Fellows of Harvard College | 5986 |
5 |
| Nippon Soda Co., Ltd. | 895 |
5 |
| Oryzon Genomics S.A. | 106 |
5 |
| F. Hoffmann-La Roche AG | 7947 |
4 |
| BASF SE | 20940 |
4 |
| Other owners | 436 |